Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 May:166:219-228.
doi: 10.1016/j.ejca.2022.01.031. Epub 2022 Mar 18.

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

Richard D Gelber  1 , Xin V Wang  2 , Bernard F Cole  3 , David Cameron  4 , Fatima Cardoso  5 , Vivianne Tjan-Heijnen  6 , Ian Krop  7 , Sherene Loi  8 , Roberto Salgado  9 , Astrid Kiermaier  10 , Elizabeth Frank  11 , Debora Fumagalli  12 , Carmela Caballero  13 , Evandro de Azambuja  14 , Marion Procter  15 , Emma Clark  16 , Eleonora Restuccia  17 , Sarah Heeson  18 , Jose Bines  19 , Sibylle Loibl  20 , Martine Piccart-Gebhart  21 ; APHINITY Steering Committee and Investigators
Affiliations
Free article
Clinical Trial

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

Richard D Gelber et al. Eur J Cancer. 2022 May.
Free article

Abstract

Aim: The APHINITY trial showed that adding adjuvant pertuzumab (P) to trastuzumab and chemotherapy, compared with adding placebo (Pla), significantly improved invasive disease-free survival (IDFS) for patients with HER2+ early breast cancer both overall and for the node-positive (N+) cohort. We explored whether adding P could benefit some N- subpopulations and whether to consider de-escalation for some N+ subpopulations.

Methods: Subpopulation Treatment Effect Pattern Plot (STEPP) is an exploratory, graphical method that plots estimates of treatment effect for overlapping patient subpopulations defined by a covariate of interest. We used STEPP to estimate Kaplan-Meier differences in 6-year IDFS percentages (P minus Pla: Δ ± standard error [SE]), both overall and by nodal status, for overlapping subpopulations defined by (1) a clinical composite risk score, (2) tumour infiltrating lymphocytes (TILs) percentage, and (3) human epidermal growth factor receptor 2 (HER2) FISH copy number. Because of multiplicity, a Δ of at least three SE is required to warrant attention.

Results: The average absolute gains in 6-year IDFS percentages were 2.8 ± 0.9 overall; 4.5 ± 1.2 for N+ and 0.1 ± 1.1 for N-. Largest gains were for patients with intermediate clinical composite risk (5.3 ± 1.9 overall; 6.9 ± 2.3 N+; 4.0 ± 3.0 N-), highest TILs percentage (6.3 ± 1.7 overall; 7.4 ± 2.4 N+; 3.2 ± 1.7 N-), and intermediate HER2 copy number (2.8 ± 1.9 overall; 7.4 ± 2.5 N+; -1.3 ± 1.9 N-), but clear evidence indicating a pattern of differential subpopulation treatment effects was lacking.

Conclusions: STEPP plots for N- did not identify subpopulations clearly benefiting from adding P, and those for N+ did not identify subpopulations warranting de-escalation. TILs percentage appeared to be more predictive of P treatment effect than clinical composite risk score.

Trial registration: clinicaltrials.gov Identifier NCT01358877.

Keywords: Adjuvant therapy; HER2-positive early breast cancer; Pertuzumab; STEPP (Subpopulation Treatment Effect Pattern Plot); TILs (tumour infiltrating lymphocytes); Trastuzumab.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement Richard D. Gelber: Research grants to institutions from Roche, Novartis, Pfizer, AstraZeneca, Merck. Xin Victoria Wang: None for this work. Bernard F. Cole: None for this work. David Cameron: Non-personal (all income to institution). Advisory/consultancy work with Roche, Novartis, Synthon, Seattle Genetics, Daiichi-Sankyo. Research funding during the life of APHINITY trial – Novartis and Roche. Stock ownership, expert testimony, directorships – NONE. Fatima Cardoso: Consultancy role for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi Sankyo, Debiopharm, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, IQVIA, MacroGenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, touchIME. Vivianne Tjan-Heijnen: Grants and personal fees from Pfizer, grants and personal fees from Roche, grants and personal fees from Novartis, grants and personal fees from E Lilly, grants from Eisai, grants and personal fees from Daiichi Sankyo, personal fees from Accord. Ian Krop: Research support (paid to his institution) from Genentech/Roche and Pfizer, has received fees from Novartis and Merck for Data Monitoring Board participation and has received consulting fees from Bristol Meyers Squibb, Daiichi/Sankyo, Macro-Genics, Context Therapeutics, Taiho Oncology, Genentech/Roche, Seattle Genetics, Celltrion and AstraZeneca. Sherene Loi: Research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Roche-Genentech, Puma Biotechnology, Eli Lilly, Nektar Therapeutics, AstraZeneca, Roche-Genentech and Seattle Genetics. She has acted as consultant (not compensated) to Seattle Genetics, Novartis, Bristol Meyers Squibb, Merck, AstraZeneca and Roche-Genentech. She has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, AstraZeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Pfizer, Gilead Therapeutics, Seattle Genetics and Bristol Meyers Squibb. She has been a Scientific Advisory Board Member of Akamara Therapeutics. She is supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York. Roberto Salgado: Non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology and Roche; advisory board fees for Bristol Myers Squibb; no COI related to this project. He is supported by a grant from the Breast Cancer Research Foundation (grant No. 17-194). Astrid Kiermaier: Employee and stockowner at F. Hoffmann-La Roche. Elizabeth Frank: None for this work. Debora Fumagalli: My institution received support from F. Hoffmann-La Roche Ltd/Genentech, Inc. for the conduct of APHINITY. My institution also receives support from F. Hoffmann-La Roche Ltd/Genentech, AstraZeneca, Novartis, Servier, Tesaro, Sanofi and Pfizer for the conduct of clinical trials. Carmela Caballero: My institution received support from F. Hoffmann-La Roche Ltd/Genentech, Inc. for the conduct of APHINITY. My institution also receives support from F. Hoffmann-La Roche Ltd/Genentech, AstraZeneca, Novartis, Servier, Tesaro, Sanofi and Pfizer for the conduct of clinical trials. Evandro Azambuja: Honoraria and/or advisory board from Roche/GNE, Novartis, Seattle Genetics, Zodiac, Libbs, Lilly and Pierre Fabre; travel grants from Roche/GNE and GSK/Novartis; research grants to my institution from Roche/GNE, AstraZeneca, GSK/Novartis and Servier. Marion Procter: M.P.'s institution received funding from Roche in respect to the APHINITY trial. Emma Clark: Employee of Roche Products Ltd. Shares in F. Hoffmann-La Roche. Issued patent: uses for and article of manufacture including HER2 dimerisation inhibitor pertuzumab, 13/649591. Eleonora Restuccia: Employment by F. Hoffmann-La Roche and stocks in F. Hoffmann-La Roche/Genentech. Sarah Heeson: Employment by Roche Products Ltd and shares in F. Hoffmann-La Roche. Jose Bines: Dr. Bines reports personal fees from Roche during the conduct of the study. Sibylle Loibl: Dr. Loibl reports grants, non-financial support and other from Roche during the conduct of the study; grants and other from AbbVie, non-financial support and other from Amgen, grants and other from AstraZeneca, other from Bayer, other from BMS, grants and other from Celgene, grants, non-financial support and other from Daiichi Sankyo, other from EirGenix, other from GSK, grants, non-financial support and other from Immunomedics/Gilead, other from Lilly, other from Merck, grants, non-financial support and other from Novartis, grants, non-financial support and other from Pfizer, other from Pierre Fabre, other from Prime/Medscape, non-financial support and other from Puma, other from Samsung, non-financial support and other from Seagen, outside the submitted work; In addition, Dr. Loibl has a patent EP14153692.0 pending, a patent EP21152186.9 pending, a patent EP15702464.7 issued, a patent EP19808852.8 pending and a patent Digital Ki67 Evaluator with royalties paid. Martine Piccart-Gebhardt: Board Member (Scientific Board): Oncolytics. Consultant (honoraria): AstraZeneca, Camel-IDS, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Pfizer, Roche-Genentech, Seattle Genetics, Immutep, Seagen, NBE Therapeutics, Frame Therapeutics. Research grants to my Institute: AstraZeneca, Immunomedics, Lilly, Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon. Speakers bureau/stock ownership: none.

Publication types

Associated data